Key result
Classic hypertrophic obstructive cardiomyopathy develops 5 years after orthotopic heart transplantation.
Case Report (n=1)
No
Highlights the rare potential for heart transplant recipients to develop de novo hypertrophic obstructive cardiomyopathy, possibly due to undetected donor genetics or immunosuppression therapy.
Answers are grounded in this paper and cite their sources.
Should not yet change post-transplant surveillance; leaves open donor genetics or immunosuppression as drivers of de novo HOCM.
The article presents a case report of developing the classic hypertrophic obstructive cardiomyopathy in a 66-year-old male heart transplant recipient within 5 years after orthotopic heart transplantation. The characteristics of this pathology are discussed.
No takes yet. Share an insight, caveat, or question.
Golovina et al. (2021) conducted a case report in Hypertrophic obstructive cardiomyopathy in heart transplant recipient (n=1). Tacrolimus was evaluated on Development of hypertrophic obstructive cardiomyopathy. A 66-year-old male developed classic hypertrophic obstructive cardiomyopathy with latent left ventricular outflow tract obstruction 5 years after orthotopic heart transplantation.
Synapse has enriched 10 related papers. Consider them for comparative context: